Evommune, Inc.
EVMN
Rank in Stocks
#15191
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Share Price
$7.65
Last synced: 2026-11-09
Market Cap
$277.63M
Change (1 day)
15.04%
Change (1 year)
-60.71%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Evommune, Inc. (EVMN)
Category
Healthcare
Operating Margin for Evommune, Inc. (EVMN)
Operating Margin as of November 2026 TTM: -1,018.93%
According to Evommune, Inc.'s latest financial reports, its current operating margin (TTM) is -1,018.93%. At the end of 2025 the company had an operating margin of -623.62%.
Operating Margin history for Evommune, Inc. from 2023 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,018.93% | 63.39% |
| 2025 | -623.62% | -37.65% |
| 2024 | -1,000.19% | 32.13% |
| 2023 | -757.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.85% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Evommune, Inc.'s operating margin
What is Evommune, Inc.'s operating margin?
Evommune, Inc.'s operating margin is -1,018.93%, as of Nov 2026.
What was Evommune, Inc.'s operating margin in 2025?
In 2025, Evommune, Inc.'s operating margin was -623.62%, compared with -1,000.19% in 2024.
How has Evommune, Inc.'s operating margin changed since 2023?
From 2023 to 2025, Evommune, Inc.'s operating margin was highest in 2025 (-623.62%) and lowest in 2024 (-1,000.19%).
How does Evommune, Inc.'s operating margin compare with similar companies?
Evommune, Inc.'s operating margin (-1,018.93%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.